Trial Profile

A First-in-Human (FIH), Open-Label, Phase 1/2 Dose Escalation and Expansion Study of ADG126, ADG126 in Combination With Anti PD1 Antibody, and ADG126 in Combination With ADG106 in Patients With Advanced/Metastatic Solid Tumors

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Muzastotug (Primary) ; ADG 106; Toripalimab
Indications Cancer; Carcinoma; Ovarian cancer; Solid tumours; Uveal melanoma
Focus Adverse reactions; First in man
Sponsors Adagene

07 Nov 2024 According to an Adagene media release, data from this trial will be presented as a poster at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, taking place in Houston, Nov. 6 - 10, 2024.
14 Aug 2024 Status changed from recruiting to completed.
06 Jun 2023 Results deriving clinical data from this and other study for assessing therapeutic window and dose selection of ADG126 , presented at the 59th Annual Meeting of the American Society of Clinical Oncology

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com